Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate Cancer

NCT04734730 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04734730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04734730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 4, 2021
Completion date
August 23, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-sensitive prostate carcinoma, metastatic prostate adenocarcinoma, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8